Licensed Research: Three Disease Discoveries -- FDA Roadmap

Bundle map placing the Diabetes, Alzheimer's, and Parkinson's discoveries on the real FDA approval road -- all at Stage 0. Licensed transfer; educational reference; not medical advice.

© CRI-ONE. All rights reserved. Patents issued and pending. Unauthorized reproduction of the underlying designs is prohibited.


Extended catalog & full narrative — Open Research: Where My Three Free Discoveries Sit on the FDA Road

The extended dossier appended from the 2026-08-05 catalog snapshot. Prices in the body copy have been stripped; the live-store price on this page is the authoritative figure. Images have been omitted.

This item is delivered by Christopher Gabriel Brown by email within 24 hours of your order. You'll receive the deliverable at the email on your order. USA delivery only. Founder Access Pass credit (code FAP99CREDIT) applies at checkout automatically.

Licensed Research  ·  FDA Approval Roadmap -- Three-Disease Bundle  ·  Patent-pending  ·  USA only
License fee
USD — Licensed transfer to a named USA buyer entity.
License terms (IP-retained model)
A purchase conveys the research package (data, formulation, patent application, drawings, scripts) plus worldwide commercialization rights to the named buyer entity. Patents and underlying IP are retained by Christopher Gabriel Brown and are NOT sold. Buyer of record must be a USA entity (up to 4 entities, joint & several). All sales final, non-refundable. All inquiries by email and postal mail only — no phone calls, no brokers, no intermediaries.

Where My Three Disease Discoveries Sit on the FDA Road

An honest map. It takes the three licensed packages — the Diabetes, Alzheimer’s, and Parkinson’s discovery packages — and places each one on the real FDA approval road. All three stand at the very start (Stage 0, Discovery). This is NOT medical advice and NOT a cure claim.

Product

Subject

Diabetes, Alzheimer’s, and Parkinson’s giveaways mapped to the FDA road

Stage on FDA road

All three at Stage 0 — Discovery / pre-IND

Inventor

Christopher Gabriel Brown, Lawrenceville, GA, USA

Price

— Licensed Research

01   How to read this set

  • The True-to-Life Method of Filing an FDA-Approved Medicine — the master guide; read it first.
  • This page — the overview of all three discoveries at once.
  • Then the deep dives: Diabetes, Alzheimer’s, and Parkinson’s on the Real FDA Road — each ending with the one lawful way to make it as a dietary supplement.

All in the Licensed Research category: cri-one.com/store/licensed-research.html.

02   The three giveaways at a glance

Giveaway

Lead direction & IP

Diabetes

Zinc-amino acid complexes + magnesium + NAC. Patent application prepared (20 claims), ready to file.

Alzheimer’s

NAC + magnesium L-threonate (memantine mechanism) + citicoline; metals excluded. Patent #19/441,975.

Parkinson’s

NAC with real human DaTscan data; a novel zinc-halogen class; iron excluded. Patent #19/445,644, Pending.

03   The map — where each one sits

Stage 0 — Discovery & Preclinical  ·  ALL THREE ARE HERE (pre-IND)
Stage 1 — IND (Form 1571) · Stage 2 — Phase 1/2/3 · Stage 3 — NDA (356h) · Stage 4 — review + cGMP · Stage 5 — decision · Stage 6 — post-market   (none yet started)

Giveaway

What is already real

What the road still needs

Diabetes

Computational discovery + human meta-analyses

GLP preclinical → IND → Phase 1–3 → NDA

Alzheimer’s

Mechanistic mapping; defensible directions

Same road; AD endpoints are notoriously hard

Parkinson’s

NAC has real human DaTscan data (outside labs)

Powered confirmatory trials → IND → NDA

04   “Patent-pending” is not “FDA-approved”

Two of these are patent-pending and the third is ready to file — but that is a different track from FDA approval. A patent (USPTO) protects an idea; it says nothing about whether the thing is safe, effective, or legal to sell as a medicine. FDA approval is the safety-and-efficacy road in the master guide. You can be fully patent-pending and still be at Stage 0.

05   If the drug road is never funded

The most likely “what-if” for an independent discovery is simply that the 10–15 year, hundreds-of-millions drug road is never funded. Three honest options remain: license/sell the IP, keep it open as licensed research, or make it as a dietary supplement — the one route that needs no FDA approval (but which, by law, can never claim to cure a disease). Each per-disease companion spells out that supplement path in detail.

Inquiries

Christopher Gabriel Brown — Inventor & Licensor

crioneaka@outlook.com  · 
1341 Wellington Cove, Lawrenceville, GA 30043-5255, USA

Related work by the same author: Chemical Cooker Laboratorycri-one.com/store/chemical-cooker-laboratory.html

Educational only. Not medical, legal, or regulatory advice; not a claim that any compound is a cure; not affiliated with or endorsed by the FDA or USPTO. The discoveries are supplement-grade research, not FDA-approved drugs. Do not self-treat; consult a licensed physician. USA buyers only; sales subject to Georgia (Gwinnett County) law.

© 2026 Christopher Gabriel Brown. All rights reserved. “Cri-One” and “Licensed Research” are product designations of the licensor. Patents retained; not sold.

Full size

© Christopher Gabriel Brown 2026

Image SHA-256 — or-giveaways-fda-map.png
a65e7aa898a7a8a7b99a4857f01fd49ae91960291544bc38d80eb24d80f833ca

Licensed Research: Three Disease Discoveries -- FDA Roadmap

$5.6K
In stock
SKU
OR-GIVEAWAYS-FDA-MAP

💳 Available Payment Options

Companies can pay via the structures below. Exact amounts and terms are set per item at agreement. Use the calculator to see approximate payments for a given total and term.

Leave blank to use the product price.
Full amount due upon agreement or by agreed date. Best for simpler deals.
Amount Due:

Sign the license agreement and complete payment via wire transfer.

Equal payments monthly (or quarterly for 24+ months).
Payment Amount:
Frequency:
Total Payments:

Sign the license agreement and complete payment via wire transfer.

Upfront fee (20-30%) + % of net revenue, with minimum annual royalty. Paid quarterly.
Upfront Fee:
Remaining (via royalty):

+ % of net revenue quarterly, with minimum annual royalty. Terms set at agreement.

Sign the license agreement and complete payment via wire transfer.

% of gross or net revenue, no/minimal upfront. Good when revenue is more predictable than milestones.
Structure: % of gross or net revenue

No or minimal upfront cost. Percentage and terms set at agreement based on projected revenue.

Sign the license agreement and complete payment via wire transfer.

Payments at key events: signing, delivery, first sale, regulatory approval, etc.
Typical Milestones:
  • Signing
  • Delivery
  • First Sale
  • Regulatory Approval

Amounts allocated per milestone at agreement. Total equals the agreed price.

Sign the license agreement and complete payment via wire transfer.

Fixed fee per year, renewable. Suits ongoing use, updates, or support. Multi-year discounts possible.
Annual Fee:
Discount:
Total over term:

Sign the license agreement and complete payment via wire transfer.

Lump sum due Net 30, Net 60, or Net 90 after agreement or delivery. Single payment, later date.
Amount Due:
Due Date:

Sign the license agreement and complete payment via wire transfer.

Bundle map placing the Diabetes, Alzheimer's, and Parkinson's discoveries on the real FDA approval road -- all at Stage 0. Licensed transfer; educational reference; not medical advice.
First to market

Publicly online since 2010 · U.S. patent applications since 2012 · inventions offered since 2014. The work of Christopher Gabriel Brown, independently documented.

First posted: · Last updated:
Links
Write Your Own Review
You're reviewing:Licensed Research: Three Disease Discoveries -- FDA Roadmap
United States sales only · USD only · Email & postal mail only, no phone · Email: crioneaka@outlook.com · 1341 Wellington Cove, Lawrenceville, GA 30043-5255, USA
Copyright © 2009-present Christopher Gabriel Brown. All rights reserved. "STRICT INTELLECTUAL PROPERTY NOTICE: All content, code, scripts, and styles in this file are the exclusive intellectual property of Christopher Gabriel Brown. DO NOT COPY, DISTRIBUTE, OR USE WITHOUT EXPRESS WRITTEN PERMISSION." Under no circumstance is there to be a transfer of Intellectual Property. Christopher Gabriel Brown presents a portfolio of advanced technologies across computing, energy, defense, and data systems. The site features products including the AutoPhi Quantum Processor (3.5 ExaFLOPS with quantum capabilities), Quantum Battery (unlimited energy storage with zero degradation), War Satellite (autonomous defense platform with global surveillance), Electric Jet (zero-emission supersonic propulsion), and specialized systems like nuclear waste recycling, blockchain security infrastructure, and smart wearable platforms. Each product includes complete documentation, manufacturing blueprints, patent protection, and implementation resources, positioning them as production-ready solutions for enterprise, government, and research applications. The collection spans quantum computing, renewable energy, aerospace, cybersecurity, and IoT, emphasizing innovation, patent protection, and technical depth. **Preferred Contact Methods** Christopher Gabriel Brown accepts communication by **email and postal mail only**. No phone calls please. **Email:** crioneaka@outlook.com **Mail:** 1341 Wellington Cove, Lawrenceville, GA 30043-5255, USA | USA-ONLY SALES | United States Dollars only | Email-only contact | No non-US orders accepted